权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Characterization of recurrent cancer mutations that cause misregulated translation

导致翻译失调的复发性癌症突变的特征

基本信息

批准号：
9978723
负责人：
Can Cenik
金额：
$ 24.9万
依托单位：
UNIVERSITY OF TEXAS AT AUSTIN
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-08-01 至 2022-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9978723
关键词：
Affect Alleles Biological Assay CRISPR/Cas technology Cancer Biology Cancer Patient Cancer cell line Catalogs Cell Line Cell Proliferation Cell Survival Cells Computational Biology Critical Pathways DNA Sequence Alteration Data Development Dimensions Disease Environment Event Funding GTP Phosphohydrolase Activators Gene Expression Genetic Genetic Determinism Genetic Transcription Genetic Variation Genomics Goals Health Horns Human Human Genetics Immunohistochemistry Impairment Individual Lead Malignant Neoplasms Malignant neoplasm of urinary bladder Measurement Measures Messenger RNA Methods Modeling Mutation Outcome Patients Phase Population Protein Array Proteins RNA RNA analysis Recurrence Recurrent Malignant Neoplasm Regulation Reporter Research Research Personnel Role Sampling Signal Pathway Signal Transduction Speed Technology Telomerase Testing The Cancer Genome Atlas Therapeutic Intervention Training Translations Untranslated RNA Variant Western Blotting anticancer research base cancer cell clinical phenotype digital experience genetic variant melanoma mutant novel polysome profiling programs public health relevance rab GTP-Binding Proteins statistics translation assay tumor progression

项目摘要

DESCRIPTION (provided by applicant): Cancer mutations can have profound consequences by causing misregulation of protein levels. For example, transcriptional regulatory mutations that increase telomerase gene expression affect ~70% of all melanoma patients and are frequent in several other cancers. While recent studies have begun to unravel the connection between genetic variation and RNA levels, protein levels often correlate poorly with RNA expression. Translation efficiency has been suggested to account for a large fraction of this discrepancy. However, little is currently known about genetic determinants of translation efficiency in humans, and their relevance to cancer. Exciting preliminary data suggests that human genetic variants can regulate translation, and importantly ~18% of all bladder cancer patients are found to harbor noncoding mutations that impair translation of a putative Rab GTPase activator. The central hypothesis of the current proposal is that genetic mutations that cause misregulated translation are functionally important in cancer. The proposed study is the logical next step towards my goal of becoming an independently funded investigator with an active research program to identify the role of genetics in controlling gene expression in cancer. While I have extensive training and experience in statistics, computational biology and genomics, I am new to cancer research. Hence, my overall objective here is to obtain additional training in cancer biology while characterizing recur- rent cancer mutations that lead to misregulated translation. To achieve my objective, I will take full ad- vantage of the excellent training environment at Stanford Universit. The expected outcomes include the functional characterization of previously unrecognized mutations affecting 18% of bladder cancer patients, and development of novel analytical and experimental methods that will pinpoint a critically missing dimension of gene expression misregulation in cancer. The proposed study will enable me to apply my training in human genetics and computational biology to an important problem while receiving additional training in cancer biology propelling me to independence. These results will have a major positive impact by enhancing our understanding of the genetic basis of translation regulation in cancer.

描述（由申请人提供）：癌症突变可能通过引起蛋白质水平的失调而产生深远的后果。例如，增加端粒酶基因表达的转录调节突变影响了约70%的黑色素瘤患者，并且在其他几种癌症中也很常见。虽然最近的研究已经开始解开遗传变异和RNA水平之间的联系，但蛋白质水平通常与RNA表达的相关性很差。翻译效率被认为是造成这种差异的主要原因。然而，目前对人类翻译效率的遗传决定因素及其与癌症的相关性知之甚少。令人兴奋的初步数据表明，人类遗传变异可以调节翻译，重要的是，发现约18%的膀胱癌患者存在非编码突变，这些突变会损害假定的Rab GT3激活剂的翻译。目前建议的中心假设是，导致错误调节翻译的基因突变在癌症中具有重要的功能。这项拟议的研究是朝着我的目标迈出的合乎逻辑的下一步，我的目标是成为一名独立资助的研究人员，拥有一个积极的研究计划，以确定遗传学在控制癌症基因表达中的作用。虽然我在统计学，计算生物学和基因组学方面有广泛的培训和经验，但我对癌症研究还是个新手。因此，我在这里的总体目标是获得癌症生物学的额外培训，表征导致错误调节翻译的复发性癌症突变。为了实现我的目标，我将充分Vantage斯坦福大学优良的培训环境。预期成果包括影响18%膀胱癌患者的先前未识别突变的功能表征，以及开发新的分析和实验方法，以确定癌症中基因表达失调的关键缺失维度。这项拟议的研究将使我能够将我在人类遗传学和计算生物学方面的培训应用于一个重要的问题，同时接受癌症生物学方面的额外培训，推动我走向独立。这些结果将通过增强我们对癌症翻译调控的遗传基础的理解产生重大的积极影响。